Roche Says Alzheimer’s Therapy Gets US Breakthrough Designation

Published on October 8, 2021

Roche said on Friday its gantenerumab antibody had received breakthrough therapy designation from the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease.

Read Full Article (External Site)